---
title: "Wanchen Biotechnology submitted an application for the issuance and listing of H shares to the Hong Kong Stock Exchange and published the application materials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258598689.md"
description: "According to the Zhitong Finance APP, Wanchen Biotechnology announced that on September 23, 2025, the company submitted an application to the Hong Kong Stock Exchange Limited (hereinafter referred to as \"Hong Kong Stock Exchange\") for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange. On the same day, the application materials for this issuance and listing were published on the Hong Kong Stock Exchange website"
datetime: "2025-09-24T00:03:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258598689.md)
  - [en](https://longbridge.com/en/news/258598689.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258598689.md)
generator: "portal-rs"
---

# Wanchen Biotechnology submitted an application for the issuance and listing of H shares to the Hong Kong Stock Exchange and published the application materials

According to the Zhitong Finance APP, Wanchen Biotechnology (300972.SZ) announced that on September 23, 2025, the company submitted an application to the Hong Kong Stock Exchange Limited (hereinafter referred to as "Hong Kong Stock Exchange") for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange. The application materials for this issuance and listing were published on the Hong Kong Stock Exchange's website on the same day

### Related Stocks

- [300972.CN](https://longbridge.com/en/quote/300972.CN.md)

## Related News & Research

- [Atrys Health Accelerates Growth and Slashes Debt in First Half of 2026](https://longbridge.com/en/news/298692631.md)
- [Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules](https://longbridge.com/en/news/298728074.md)
- [Serina Therapeutics Inc Reports Cohort 1 Observations From Ser-252 Registrational Study In Advanced Parkinson’S Disease And Advances To Cohort 2](https://longbridge.com/en/news/298452346.md)
- [Matica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovation](https://longbridge.com/en/news/298444718.md)
- [National Franchise T.A.C.T. Celebrates Franchisee Feature in Esquire Magazine Highlighting Industry Excellence](https://longbridge.com/en/news/298459621.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**